Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
HKG: 1801
Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...
Innovent Biologics Denies Lab Closure, Confirms Relocation to California
Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...
Innovent Biologics Allegedly Closes US Research Facility, Shifts Focus to China
Innovent Biologics (HKG: 1801), a China-based biotech firm, has reportedly closed down a research team...
Innovent and HutchMed’s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer
China’s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics...
Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...
Innovent Biologics Launches Phase I Study for IBI3002, a Bispecific Antibody Targeting Asthma
Innovent Biologics, Inc. (HKG: 1801), based in China, has announced the initiation of its Phase...
Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037
Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical...
Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...
Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales
Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...
Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors
Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...
Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....
HutchMed’s Elunate-Tyvyt Combination Study for Renal Cell Carcinoma Completes Enrollment
China-based HutchMed (NASDAQ: HCM) has announced the completion of patient enrollment in its Phase II/III...
Innovent Biologics Expands Partnership with Synaffix for New ADC Development
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...
AnHeart Therapeutics and Innovent Biologics File Taletrectinib for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has indicated on its website that taletrectinib, an ROS1/NTRK...
Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...